MYIA
GTBP icon

Mount Yale Investment Advisors’s GT Biopharma GTBP Stock Holding History

Mount Yale Investment Advisors’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-46
Closed -$165 – 1052
2025
Q2 		$165 Buy
+46
New +$119 ﹤0.01% 1461

Other funds holding GTBP

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Mount Yale Investment Advisors's GTBP Position: Q3 2025 in Review

Mount Yale Investment Advisors sold out of GT Biopharma (GTBP) in Q3 2025, closing a stake of 46 shares — an estimated $165 sold.

Mount Yale Investment Advisors first reported a position in GTBP in Q2 2025 and held it in 1 quarter. The position peaked at $165 in Q2 2025. 21 funds tracked by Wall St. Rank hold GTBP as of Q3 2025.

  • Mount Yale Investment Advisors reported no remaining GT Biopharma position as of Q3 2025 after selling out during the quarter.
  • Mount Yale Investment Advisors sold 46 GT Biopharma shares in Q3 2025, an estimated $165.
  • Mount Yale Investment Advisors first reported a position in GT Biopharma in Q2 2025 and held it in 1 quarter.
  • Mount Yale Investment Advisors's GT Biopharma position peaked at $165 in Q2 2025.
  • 21 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2025.

Based on Mount Yale Investment Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.